Why phase II trials in cervical chemoprevention are negative: what have we learned?

Author： Follen M.  

Publisher： Springer Publishing Company

ISSN： 0957-5243

Source： Cancer Causes and Control, Vol.13, Iss.9, 2002-11, pp. : 855-873

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tomato-based food products for prostate cancer prevention: what have we learned?

By Tan Hsueh-Li  

Cancer and Metastasis Reviews, Vol. 29, Iss. 3, 2010-09 ,pp. : 553-568

Springer Publishing Company

Access to resources Recommend Favorite

Thyroid cancer pooled analysis from 14 case–control studies: what have we learned?

By Preston‐Martin Susan  

Cancer Causes and Control, Vol. 14, Iss. 8, 2003-01 ,pp. : 787-789

Springer Publishing Company

Access to resources Recommend Favorite

Clinical Trials with Retrovirus Mediated Gene Therapy – what Have we Learned?

By Rainov Nikolai G.   Ren Huan  

Journal of Neuro-Oncology, Vol. 65, Iss. 3, 2003-12 ,pp. : 227-236

Springer Publishing Company

Access to resources Recommend Favorite

What have we learnt from previous phase II trials to help in the management of childhood brain tumours?

By Chastagner P.   Bouffet E.   Grill J.   Kalifa C.  

European Journal of Cancer, Vol. 37, Iss. 16, 2001-11 ,pp. : 1981-1993

Elsevier

Access to resources Recommend Favorite

Chemotherapy for advanced and recurrent cervical carcinoma in the new era of upfront chemotherapy and radiation: Have we arrived?

By Monk Bradley  

The Women's Oncology Review, Vol. 5, Iss. 2, 2005-06 ,pp. : 77-80

Informa Healthcare

Access to resources Recommend Favorite